Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃
Fuziline is a natural alkaloid product isolated from the lateral roots of the traditional Chinese medicine Aconitum carmichaelii Debx. Fuzi, as an important warming herb in traditional Chinese medicine, has always been used to treat cold dampness pain, rheumatoid arthritis, and cardiovascular diseases. Fuziling, as one of its main active ingredients, has gradually become a research hotspot in the fields of natural product pharmacology and new drug development in recent years due to its significant analgesic activity and low toxicity risk. This article will provide a systematic review of the chemical structure, pharmacological activity, mechanism of action, and pharmacological properties of Fuziling, aiming to provide theoretical basis and research ideas for its clinical development and drug design.
The chemical structure of Fuzilin belongs to the dihydroisoquinoline alkaloid class, with a molecular formula of C27H37NO5 and a molecular weight of 453.5760. Its structure contains multiple cyclic structures and functional groups, endowing it with unique physicochemical properties. The LogP value of Fuziling is 0.8918, indicating that it has moderate lipid solubility, which is beneficial for cell membrane penetration but not excessively hydrophobic; The TPSA (topological polar surface area) is 111.85 Å ², indicating moderate polarity that may affect its binding affinity and pharmacokinetic behavior with biological targets. The water solubility is 2.6537, indicating that it has a certain solubility in the aqueous phase, which is beneficial for absorption in vivo. The low permeability of the blood-brain barrier suggests that the direct action of the central nervous system may be limited, but its potential for action on the peripheral nervous system is greater. The negative result of hERG channel inhibition experiment indicates that Fuziling has a low risk of cardiac toxicity; The Ames test result is 0.0, indicating no significant genotoxicity risk.
Fuziling mainly comes from the lateral roots of Aconitum plants. Fuzi belongs to the Aconitum genus of the Ranunculaceae family and is widely distributed in the Yangtze River Basin and its southern regions of China. In traditional Chinese medicine processing techniques, aconite undergoes complex steaming and processing processes to reduce its toxicity and retain its active ingredients. The extraction of Fuziling is generally carried out using organic solvent extraction method, with methanol or ethanol commonly used as extraction agents, combined with ultrasound assisted extraction to improve extraction efficiency. The extraction solution undergoes liquid-liquid distribution, column chromatography, and other separation and purification steps, and is ultimately identified and quantified using techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry (MS). In recent years, the application of supercritical fluid extraction and molecular imprinting technology has provided new methodological support for the high-purity and efficient extraction of Fuzilin.
The main pharmacological activity of Fuziling is focused on its analgesic effect. Multiple in vitro and in vivo experiments have shown that Fuziling can significantly alleviate inflammatory and neuropathic pain, and its analgesic effect is comparable to traditional opioid drugs, but the side effects are relatively mild. In animal models, Fuziling showed good inhibitory effects on pain responses induced by thermal, mechanical, and chemical stimuli. In addition, Fuziling also exhibits certain anti-inflammatory activity, which can inhibit the release of inflammatory mediators and alleviate tissue inflammatory reactions.
In terms of neuroprotection, Fuziling exhibits potential neural repair effects by regulating neurotransmitter release and neuroinflammatory responses. Some studies also suggest that it may have certain antidepressant and anti anxiety effects, suggesting its potential application in central nervous system diseases.
The analgesic mechanism of Fuziling is complex, involving multiple molecular targets and signaling pathways. Its main targets include:
The multiple regulation of these targets endows Fuziling with significant analgesic effects, while reducing the risk of drug resistance and side effects that may arise from single target drugs.
The pharmacological parameters of Fuziling indicate that it has good potential for drug development. Moderate molecular weight and LogP value are beneficial for its in vivo distribution and cell membrane penetration. The high TPSA and water solubility ensure its solubility and bioavailability in body fluids. The low permeability of the blood-brain barrier suggests that it mainly acts on the peripheral nervous system, reducing the risk of toxic side effects in the central nervous system.
Toxicological evaluation shows that Fuzilin has no significant cardiac toxicity (hERG channel inhibition negative) and genotoxicity (Ames test negative), providing preliminary safety assurance. Pharmacokinetic studies have shown that Fuzilin has a moderate half-life in the body, can maintain effective blood drug concentrations, and is excreted after liver metabolism, with good safety of metabolites.
However, the low blood-brain barrier permeability of Fuziling may limit its application in certain central diseases, and its pharmacokinetic properties can be optimized in the future through structural modifications or carrier systems.
Fuziling, as a natural alkaloid, has significant analgesic and anti-inflammatory activities, high safety, and broad clinical application prospects. Its potential therapeutic effect in chronic pain, neuropathic pain, rheumatoid arthritis and other diseases is particularly suitable for patients with poor tolerance or significant side effects to traditional opioid drugs. In addition, Fuziling regulates various neurotransmitters and receptors, indicating its potential for development in neurological diseases such as depression and anxiety.
Future research should focus on:
In summary, Fuziling, as a natural product with unique pharmacological activity, is expected to become a new generation of safe and efficient analgesic drugs in the future.
As an important alkaloid in Aconitum, Fuzilin has demonstrated high drug development value due to its multi-target analgesic mechanism and good safety. This article systematically reviews the chemical structure, plant origin, pharmacological activity, mechanism of action, and pharmacological evaluation of Fuziling, emphasizing its potential applications in pain management and neurological diseases. Although clinical research on Fuzilin is still in its infancy, with the continuous advancement of modern pharmacology and medicinal chemistry technology, Fuzilin is expected to become a star molecule in the field of natural product pharmacology, providing new strategies and choices for pain treatment and related disease management. Future research needs to further deepen its mechanism of action, optimize its pharmacokinetic properties, and promote clinical translation to maximize its clinical value.
